Loading
Ironwood Pharmaceuticals Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 08 Mar 2024.
Ironwood Pharmaceuticals Inc: what insiders have been doing
Every trade that managers of Ironwood Pharmaceuticals Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Cambridge, United States. It was founded in 1998. From 18 October 2025 to 18 October 2026, the disclosure feed for Ironwood Pharmaceuticals Inc logged 26 filings by 13 insiders.
Only sales appear on the open market, 9 sales in all totalling €1.2M, filed by 6 insiders. At €505k, the sale published on 9 July 2026 by Silver Ronald is the largest of the period (0.081% of market cap).
Compared with its exchange (5,458 companies, median 22 filings), a count of 26 filings is above the norm. Our records for Ironwood Pharmaceuticals Inc go back to 2016, with 3 purchases and 87 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 296.2 m USD and net income of 24.0 m USD.
Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
225
Thresholds
n/a
Buy Volume
€430,026
3 ops. · all time
Sell Volume
€14M
87 ops. · all time
Who traded when
BuySaleRonald Silver5 sales
Tammi L. Gaskins4 sales
Gregory S. Martini3 sales
Thomas A. MCCOURT3 sales
Minardo John2 sales
Davis Andrew1 sale
+2 other insiders
Since the insiders bought
- -84.0%Entry US$8.95 · Close at T+365 US$1.43
- -83.2%Entry US$8.93 · Close at T+365 US$1.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 11,008 of 24,148 companies
53.8
score / 100
Value68
Quality40
FCF yld22%
Earn yld4.2%
EV/EBITDA11.2x
ROE·
Gross mgn·
Net mgn8.1%
Debt/EBITDA5.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.50
Analyst consensus
4 analysts2.25/5
US$3.70Target US$6.10(+74%)US$10.00
Income statement
RevenueUS$296.2M
Gross profitUS$410.6M139% margin
EBITDAUS$104.7M35% margin
Net incomeUS$24M33.4% margin
Valuation
PER (trailing)4.5x
PER (forward)2.3x
Beta0.22
Balance sheet & cash
Market capUS$578.3M
Total debtUS$597.8M
Free Cash FlowUS$127M
Profitability & ownership
ROA47.0%
% insiders3.2%
% institutions99.1%
Last declaration on 23 September 2026
Declarations225 total
83,306 shares@ US$4.53Class A Common StockSEC144:0001808509-26-000003
3,694 shares0Class A Common StockSEC:0001193125-26-394323:0
137,036 shares0Class A Common StockSEC:0001193125-26-312410:0
127,890 shares@ US$4.520.081% mcap52.4% of flowClass A Common StockSEC:0001193125-26-299749:0
127,890 shares@ US$4.380.080% mcap100.0% of flowCommonSEC144:0001950047-26-006947
63,481 sharesClass A Common StockSEC:0001193125-26-274288:0
4,065 sharesClass A Common StockSEC:0001193125-26-274279:0
63,481 sharesClass A Common StockSEC:0001193125-26-274279:1
63,481 sharesClass A Common StockSEC:0001193125-26-274283:0
21,571 shares@ US$3.690.011% mcap100.0% of flowCommonSEC144:0001950047-26-006206
4,451 shares0Class A Common StockSEC:0001193125-26-111581:0
136,612 shares0Class A Common StockSEC:0001193125-26-104112:0
163,934 shares0Class A Common StockSEC:0001193125-26-104110:0
136,612 shares0Class A Common StockSEC:0001193125-26-104108:0
136,612 shares0Class A Common StockSEC:0001193125-26-104107:0
409,836 shares0Class A Common StockSEC:0001193125-26-104099:0
136,612 shares0Class A Common StockSEC:0001193125-26-104111:0
11,552 shares@ US$3.813.9% of flowClass A Common StockSEC:0001193125-26-071495:0
17,439 shares@ US$3.815.3% of flowClass A Common StockSEC:0001193125-26-071509:0
10,287 shares@ US$3.8163.0% of flowClass A Common StockSEC:0001193125-26-071500:0
94,757 shares@ US$3.813.5% of flowClass A Common StockSEC:0001193125-26-071496:0
10,487 shares@ US$3.8161.1% of flowClass A Common StockSEC:0001193125-26-071515:0
15,570 shares@ US$3.814.7% of flowClass A Common StockSEC:0001193125-26-071503:0
35,416 shares@ US$4.6014.4% of flowClass A Common StockSEC:0001193125-26-006290:0
4,178 shares0Class A Common StockSEC:0001193125-25-322690:0
25 of 225 declarations
About Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals Inc. is a U.S.-based biopharmaceutical company listed on the **NASDAQ (IRWD)** in the **United States**, headquartered in **Boston, Massachusetts**, with additional operations in **Basel, Switzerland**. Founded in **1998**, Ironwood has evolved into a focused gastrointestinal (GI) and rare-disease specialist rather than a broad diversified pharmaceutical company. For investors, it represents a mid-cap commercial biotech profile: a revenue base supported by a marketed brand, paired with a targeted pipeline that offers upside but also carries meaningful regulatory and clinical execution risk.
The company’s business model is centered on two main pillars. The first is **LINZESS® (linaclotide)**, Ironwood’s flagship commercial product and one of the most important assets in its history. LINZESS is a leading prescription therapy in the United States for adults with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Ironwood helped discover, develop, and commercialize the brand, and in the U.S. it is marketed through a collaboration with **AbbVie**, which means Ironwood records collaboration revenue tied to U.S. sales rather than running a fully independent direct-sales model. This structure supports a recurring revenue stream while reducing some of the commercial burden that a standalone launch organization would normally bear.
Read moreShow less
The second pillar is **apraglutide**, a once-weekly, long-acting synthetic GLP-2 analog being developed for patients with short bowel syndrome with intestinal failure who depend on parenteral support. Apraglutide is the company’s key development asset and the most important medium-term growth driver. It reflects Ironwood’s longstanding focus on GI therapeutics and rare GI diseases, an area where specialized expertise and clinical differentiation can create meaningful value.
From a competitive standpoint, Ironwood is positioned as a GI-focused innovator with a relatively concentrated portfolio. Its strengths include deep domain expertise, an established commercial product, and a history of executing in digestive-disease therapeutics. Its competitive moat is narrower than that of large-cap pharma peers, but its specialization allows it to target areas with significant unmet medical need. The company’s performance is therefore highly sensitive to LINZESS trends, payer dynamics, and the success of apraglutide’s clinical and regulatory path.
Recent developments have been important. In 2025 and early 2026, Ironwood reported strong LINZESS prescription demand trends in the U.S., while also progressing apraglutide after discussions with the FDA and preparation for a confirmatory Phase 3 program. The company also highlighted a pediatric label expansion for LINZESS, broadening the product’s commercial opportunity. For investors, Ironwood combines near-term cash generation from an established GI franchise with pipeline optionality in a rare-disease setting, making it a focused but not low-risk healthcare equity.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
